FYI, the EMPA-REG Outcome Trial in diabetic patients treated with the SGLT2 inhibitor Jardiance was based on the 3-point MACE (death, non-fatal myocardial infarction, non-fatal stroke). The full detailed results will be disclosed this Thursday at the EASD meeting and there is a webcast available if interested. This will #1 give us a good idea of what the MACE incidence rate is for the 3-point MACE endpoints in a diabetic population and #2 let us know what kind of beneficial effect that Jardiance provided. So far, only the top line generic statement "Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events" has been disclosed.

Resverlogix in BETonMACE will be using a similar 3-point MACE target and using a diabetic (and low HDL) patient population.